312 results on '"DEL PRATO, Stefano"'
Search Results
2. β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin
3. Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
4. Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients
5. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
6. 422-P: Predictive Role of Triglyceride-Glucose Index on All-Cause Mortality and Incidence of Vascular Events in Type 2 Diabetes (T2D) : A 13-Year Follow-Up Observational Study
7. 97-OR: Fatty Liver Index (FLI) Is an Independent Risk Factor for All-Cause Mortality and Cardiovascular Events in Type 1 Diabetes (T1D) : A 10-Year Observational Study
8. 258-OR: Sustainability of HbA1c Control of Tirzepatide vs. Insulin Glargine in People with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
9. 749-P: Clinically Relevant Predictors of Cardiovascular Events: Exploratory Analysis from the VERIFY Study of Initial Treatment of Type 2 Diabetes Mellitus
10. 54-LB: Distinct Mechanisms Are Responsible for the Increase in Endogenous Glucose Production and Ketone Formation following Empagliflozin in T2DM Patients
11. 90-LB: Characterization of Tirzepatide-Treated patients achieving HbA1c <5.7% in the SURPASS 1-4 Trials
12. COVID-19, Hyperglycemia, and New-Onset Diabetes
13. 986-P: Evaluation of Cardiovascular Risk and All-Cause Mortality in Type 1 Diabetes: Comparison of Risk Engines in a 10-Year Follow-up
14. Erratum. Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. Diabetes Care 2021;44:1062–1069
15. Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes Care 2020;43:e139–e141
16. Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis
17. Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?
18. Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
19. Insulin as an early treatment for type 2 diabetes: origin or end of an old question?
20. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care editors' expert forum
21. Pathogenetic mechanisms and cardiovascular risk: differences between [HbA.sub.1c] and oral glucose tolerance test for the diagnosis of glucose tolerance
22. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study
23. Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters
24. Reinterpreting Cardiorenal Protection of Renal Sodium–Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming
25. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial
26. Multidrug treatment of type 2 diabetes: a challenge for compliance
27. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/ mortality? Yes
28. Changing the treatment paradigm for type 2 diabetes
29. Primary prevention of cardiovascular disease in people with dysglycemia
30. Normal glucose tolerance and gestational diabetes mellitus: what is in between?
31. An off-the-shelf instant contact casting device for the management of diabetic foot ulcers: a randomized prospective trial versus traditional fiberglass cast
32. The beneficial effects of pancreas transplant alone on diabetic nephropathy
33. Functional and molecular defects of pancreatic islets in human type 2 diabetes
34. Semiquantitative analysis of the histopathological features of the neuropathic foot ulcer: effects of pressure relief
35. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis
36. A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects. (Brief Genetics Report)
37. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that β-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated
38. Insulin secretory function is impaired in isolated human islets carrying the [Gly.sup.972] → Arg IRS-1 polymorphism. (Brief Genetics Report)
39. Lipotoxicity in human pancreatic islets and the protective effect of metformin
40. Phasic insulin release and metabolic regulation in type 2 diabetes
41. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial
42. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria
43. Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients
44. Bedtime insulin daytime glipizide: effective therapy for sulfonylurea failures in NIDDM
45. Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction
46. In vivo glucose metabolism in obese and type II diabetic subjects with or without hypertension
47. Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women
48. Ketone body metabolism in NIDDM: effect of sulfonylurea treatment
49. How do we define cure of diabetes? (CONSENSUS STATEMENT: Reviews/Commentaries/ADA Statements)
50. Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.